- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
TCRX
NASDAQ
Week ended 24 Jul 2026
Weekly Investor Report
Tscan Therapeutics Inc · Healthcare · Biotechnology
Latest close
0.79 USD
-13.2%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -24.4% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -13.2%, after a -18.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 13d.
Setup score
22
out of 100
Latest Close
0.79 USD
24 Jul 2026
1W Return
-13.2%
latest completed week
4W Return
-18.0%
short-term follow-through
12W Return
-34.9%
quarterly tape
Trend Breadth
21.2%
11 of 52 weeks active
Volume Ratio
0.9x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
-13.2%
Latest completed week; four-week move -18.0%.
Indicator stack
12/48
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
News sentiment
55/100
58 relevant articles in the latest sentiment read.
Event risk
13d
Next report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -24.4% below the Trend Line and sits at 0.2% of its 52-week range. The latest completed week returned -13.2%, after a -18.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.9x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
30 Jan
6 Feb
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.1912-week average 0.21
12-week confirmation
Trend active1/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure7/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.19Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -18.0% over four weeks, -34.9% over 12 weeks, and -58.9% over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year11
Trend breadth21.2%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-0.21Latest activity-pressure read.
Pressure change26.4%Four-week change in activity pressure.
Leadership-44.24Latest relative-leadership reading.
RS change-15.7%Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 26 Jul 2026
Financial statements through 31 Dec 2025
Field coverage 85%
Model confidence 81%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength32/100Blend of value, momentum, and quality. Underlying universe rank 69; rank 1 is best.
Value42/100Relative valuation strength. Underlying universe rank 59; rank 1 is best.
Quality41/100Profitability and accounting quality. Underlying universe rank 60; rank 1 is best.
Momentum42/100Medium-term price momentum. Underlying universe rank 59; rank 1 is best.
Growth42/100Revenue and earnings growth. Underlying universe rank 59; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- - Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- 92.4% Gross profit retained from each unit of revenue.
- Operating margin
- -1330.2% Operating profit retained from revenue.
- Free-cash-flow margin
- -1303.3% Free cash flow generated from revenue.
- Return on invested capital
- -148.4% Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- 106.7% Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 2/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- 0.0% Cash dividends relative to market value.
- Buyback yield
- - Net share repurchases relative to market value.
- Shareholder yield
- - Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 0.3x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Insider activity6 / 0
6 acquisitions and 0 disposals in the latest 180-day insider tape.
Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.News sentiment55/100
Weighted news tone is neutral across 58 relevant articles.
21 positive · 32 neutral · 5 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-69.1%Distance below the 52-week high.
13-week volatility9.0%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
30 Jan
27 Feb
27 Mar
24 Apr
22 May
19 Jun
24 Jul
Weeks higher15 of 2611 weeks finished lower.
Best week+13.3%Week of 17 Apr.
Worst week-20.6%Week of 15 May.
Latest week-13.2%Week of 24 Jul.
Shape of recent returns
Strong gains8
Modest gains7
Flat weeks0
Modest losses2
Sharp losses9
Recent vol9.0%13-week weekly-return volatility.
Base vol10.9%52-week weekly-return volatility.
Up/down split29/23Count of positive and negative weeks in the 52-week window.
Average skew6.4% / -10.4%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average1.3%
Trend breadth51.0%
Trend51.0%active weekly trend signals
MD75.0%positive activity pressure
RS48.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth67.0%
Trend67.0%active weekly trend signals
MD72.0%positive activity pressure
RS65.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape25/100
Trend, activity pressure, participation, and risk combine to a 25/100 tape read.
Indicator analysis26/100Latest 12-week confirmation: trend 1/12, activity pressure 7/12, relative leadership 0/12.
Activity pressure 0.19; No reversal markers Factors38/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 50; Small Cap Core rank 59 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Sentiment55/100Weighted news tone is neutral across 58 relevant articles.
TScan Therapeutics Inc (TCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk Insiders6 / 06 acquisitions and 0 disposals in the latest 180-day insider tape.
Earnings13dNext report is scheduled for 11 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 24 Jul 2026 | 0.79 USD | -13.2% | 1.05 USD | 3.37 USD | -0.21 | -44.24 | 3.1M | Off |
| 17 Jul 2026 | 0.91 USD | -16.1% | 1.06 USD | 3.38 USD | 0.00 | -38.08 | 4.1M | Off |
| 10 Jul 2026 | 1.09 USD | 2.8% | 1.06 USD | 3.38 USD | -0.00 | -30.51 | 5.9M | Off |
| 3 Jul 2026 | 1.06 USD | 9.4% | 1.06 USD | 3.39 USD | -0.23 | -32.26 | 4.9M | Off |
| 26 Jun 2026 | 0.97 USD | 5.3% | 1.06 USD | 3.40 USD | -0.29 | -38.23 | 3.9M | Off |
| 19 Jun 2026 | 0.92 USD | 0.9% | 1.06 USD | 3.41 USD | -0.10 | -44.55 | 2.5M | Off |
| 12 Jun 2026 | 0.91 USD | -7.1% | 1.06 USD | 3.42 USD | 0.17 | -44.28 | 1.6M | Off |
| 5 Jun 2026 | 0.98 USD | -9.1% | 1.07 USD | 3.43 USD | 0.39 | -39.49 | 2.1M | Off |
| 29 May 2026 | 1.08 USD | 1.9% | 1.07 USD | 3.44 USD | 0.77 | -37.50 | 1.5M | On |
| 22 May 2026 | 1.06 USD | 6.0% | 1.10 USD | 3.45 USD | 0.93 | -37.55 | 2.6M | Off |
| 15 May 2026 | 1.00 USD | -20.6% | 1.14 USD | 3.47 USD | 1.15 | -40.96 | 4.1M | Off |
| 8 May 2026 | 1.26 USD | 3.3% | 1.19 USD | 3.48 USD | 1.38 | -26.43 | 4.6M | Off |
| 1 May 2026 | 1.22 USD | -3.2% | 1.22 USD | 3.50 USD | 1.19 | -25.35 | 3.0M | Off |
| 24 Apr 2026 | 1.26 USD | 5.9% | 1.25 USD | 3.51 USD | 0.92 | -22.62 | 7.3M | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.